WB100 / Weben Pharma - LARVOL DELTA

Clinical Trial of WBC100 on Advanced Solid Tumor (clinicaltrials.gov) - P1 | N=68 | Terminated | Sponsor: Zhejiang University | Recruiting ➔ Terminated; sponsor's decision to change development strategy (the QOD cohort was completed).

Trial termination • Solid Tumor • CA 19-9 • MYC

Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Hangzhou Weben Pharma Co., Ltd

New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Safety and efficacy of a small-molecule c-Myc degrader WBC100 in solid tumors: A first-in-human, phase I trial. (ASCO 2025) - P1 | "WBC100 showed a tolerable safety profile and preliminary anti-tumor activity in advanced solid tumors especially in PDAC. Dose escalation is ongoing and expected to proceed to dose expansion soon. To our knowledge, this is the first study of a small-molecule c-Myc degrader for further clinical development in cancer."

Clinical • P1 data • Anemia • Fatigue • Hepatocellular Cancer • Leukopenia • Neutropenia • Oncology • Pancreatic Cancer • Renal Disease • Small Intestinal Carcinoma • Solid Tumor • Thrombocytopenia • MYC

Clinical Trial of WBC100 on Advanced Solid Tumor (clinicaltrials.gov) - P1 | N=90 | Recruiting | Sponsor: Zhejiang University | N=60 ➔ 90 | Trial completion date: Oct 2023 ➔ Oct 2025 | Trial primary completion date: Oct 2023 ➔ Oct 2025

Enrollment change • Trial completion date • Trial primary completion date • Oncology • Solid Tumor • MYC

Clinical Trial of WB100 on Advanced Solid Tumor (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Zhejiang University | Not yet recruiting ➔ Recruiting

Enrollment open • Gastrointestinal Cancer • Oncology • Solid Tumor • Cancer antigen 19-9 • MYC

A Selective Small-Molecule c-Myc Degrader Potently Regresses Lethal c-Myc Overexpressing Tumors. (PubMed, Adv Sci (Weinh)) - "In vivo, WBC100 potently regresses multiple lethal c-Myc overexpressing tumors such as acute myeloid leukemia, pancreatic, and gastric cancers with good tolerability in multiple xenograft mouse models. Identification of the NLS1-Basic-NLS2 region as a druggable pocket for targeting the "undruggable" c-Myc protein and that single-agent WBC100 potently regresses c-Myc overexpressing tumors through selective c-Myc proteolysis opens new perspectives for pharmacologically intervening c-Myc in human cancers."

Journal • Acute Myelogenous Leukemia • Gastric Cancer • Gastrointestinal Cancer • Hematological Malignancies • Leukemia • Oncology • Pancreatic Cancer • Solid Tumor • Targeted Protein Degradation • MYC